ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 697

Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit

Clara Pérez-Velásquez1, Maria Luz Garcia Vivar2, Silvia Perez Barrio3, Eva Galindez-Agirregoikoa1, Esther Ruíz Lucea1, Ignacio Torre-Salaberri4, Olaia Fernández-Berrizbeitia1, Ana Rosa Inchaurbe Pellejero2, Juan Blanco Madrigal1, Edurne Guerrero Basterretxea2, Itziar Calvo Zorrilla2, Oihane Ibarguengoitia2, David Montero2, Natalia Rivera-García1, Maria Jesus Allande Lopez Linares1 and Iñigo Gorostiza-Hormaetxe5, 1Rheumatology, University Hospital of Basurto, Bilbao, Spain, 2Rheumatology, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, 3Dermatology, University Hospital of Basurto, Bilbao, Spain, 4Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 5Unit of Research, University Hospital of Basurto, Bilbao, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: DMARDs, psoriasis, psoriatic arthritis and skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: We consider multidisciplinary management necessary, especially in a subgroup of patients with Psoriatic Arthritis (PsA) for complexity, cutaneous and / or joint involvement. Despite the limited evidence of efficacy of methotrexate (MTX) and other classical synthetic DMARDs (csDMARDs) in these patients, they are commonly prescribed in our multidisciplinary unit (following the recommendations of experts, in peripheral PsA). Objective: To assess joint and cutaneous involvement in patients with peripheral psoriatic arthritis not receiving biologics in our multidisciplinary unit (visited for at least 6 months)

Methods: We review clinical the records of 199 PsA patients visited in our multidisciplinary unit and select 74 patients with the above mentioned criteria; we collect epidemiological and clinical data, and joint and skin activity evaluation by DAPSA, PASI, BSA and PGA (in plaque psoriasis) and proportion of patients that achieve MDA (minimum disease activity) as a therapeutic goal. Data were analyzed using SPSSv23.

Results: 74 patients, 63.5% males, aged mean(SD) 54.8(14.0) years. 56 peripheral PsA and 18 mixed (peripheral predominance); with mean 94.9(92.4) months of disease; 35.1% with previous clinical enthesitis and 37.8% previous dactylitis. Cutaneous disease consisted mainly (82.4%) in plaque psoriasis, 9.5% affecting folds, 4.1% onychopathy. 52,7% have received a previous DMARD of (31.1% MTX, 9.5% leflunomide) and 23.0% PUVA; 4.1% have received previous biological treatment. Current treatment: 83.8% DMARDs (68.9% MTX and 5.4% leflunomide) with a mean follow-up of 60.6(55.0) months. Disease activity: Skin plaque psoriasis was mainly controlled: 73.4% low PASI level (23.4% moderate) median PASI 3.0 [1.5-5.0]; 50.0% mild BSA, median BSA 3.0[1.0-6.0]. 73.1% PGA of very mild or mild-moderate disease. 87.0% of patients met DAPSA criteria of remission-low disease activity (DAPSA median 3.15[1.34-6.71]; 55.9% achieved DAPSA <4); 75.7% were in low activity / remission according to medical judgement. Overall 63.9% of patients achieved MDA; 15.3% (10 patients) had relative” contraindications” to biological therapy (6 cases of recent cancer, 2 HBV infection).

Conclusion: Over half of PsA patients from our multidisciplinary unit achieve low cutaneous and articular disease activity under csDMARDs, mainly Methotrexate. The use of targeted DMARDs such as apremilast in this scenario before biological therapies may improve disease outcomes in a subgroup of patients, corresponding with the efficacy shown in different domains of the psoriatic disease. Further research is needed to compare clinical results between csDMARDs and Apremilast.


Disclosure: C. Pérez-Velásquez, None; M. L. Garcia Vivar, None; S. Perez Barrio, None; E. Galindez-Agirregoikoa, None; E. Ruíz Lucea, None; I. Torre-Salaberri, None; O. Fernández-Berrizbeitia, None; A. R. Inchaurbe Pellejero, None; J. Blanco Madrigal, None; E. Guerrero Basterretxea, None; I. Calvo Zorrilla, None; O. Ibarguengoitia, None; D. Montero, None; N. Rivera-García, None; M. J. Allande Lopez Linares, None; I. Gorostiza-Hormaetxe, None.

To cite this abstract in AMA style:

Pérez-Velásquez C, Garcia Vivar ML, Perez Barrio S, Galindez-Agirregoikoa E, Ruíz Lucea E, Torre-Salaberri I, Fernández-Berrizbeitia O, Inchaurbe Pellejero AR, Blanco Madrigal J, Guerrero Basterretxea E, Calvo Zorrilla I, Ibarguengoitia O, Montero D, Rivera-García N, Allande Lopez Linares MJ, Gorostiza-Hormaetxe I. Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/clinical-results-of-patients-with-peripheral-psoriatic-arthritis-not-receiving-biological-therapy-in-a-multidisciplinary-unit/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-results-of-patients-with-peripheral-psoriatic-arthritis-not-receiving-biological-therapy-in-a-multidisciplinary-unit/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology